In vitro activity of dalbavancin against drug-resistant Staphylococcus aureus Isolates from a global surveillance program

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 8, 2015, Pages 5007-5009

  McCurdy, Sandra P ^a   Jones, Ronald N ^b   Mendes, Rodrigo E ^b   Puttagunta, Sailaja ^a   Dunne, Michael W ^a  

^a Durata Therapeutics   (United States)

^b JMI LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINDAMYCIN; DALBAVANCIN; DAPTOMYCIN; LINEZOLID; TIGECYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT; MINOCYCLINE; TEICOPLANIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; COMPARATIVE STUDY; DRUG SURVEILLANCE PROGRAM; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROCEDURES; QUALITY CONTROL; ANALOGS AND DERIVATIVES; DRUG EFFECTS; EPIDEMIOLOGICAL MONITORING; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; STAPHYLOCOCCAL INFECTIONS; UNITED STATES;

ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EPIDEMIOLOGICAL MONITORING; HUMANS; LINEZOLID; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; STAPHYLOCOCCAL INFECTIONS; TEICOPLANIN; UNITED STATES;

EID: 84939817790     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00274-15     Document Type: Article

References (10)

1. Boucher H, Miller LG, Razonable RR. 2010. Serious infections caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 51(Suppl 2): S183-S197. http://dx.doi.org/10.1086/653519.
2. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. 1997. Methicillin-resistant Staphylococcus aureus clinical strains with reduced vancomycin susceptibility. J Antimicrob Chemother 40:135-136. http://dx.doi.org/10.1093/jac/40.1.135.
3. Moellering RC, Jr. 2012. MRSA: the first half century. J Antimicrob Chemother 67:4-11. http://dx.doi.org/10.1093/jac/dkr437.
4. Dalvance. 2014. Dalvance (dalbavancin) for injection, for intravenous use. Durata Therapeutics U.S. Limited, Chicago, IL. http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/021883s000lbl.pdf.
5. Ciabatti R, Malabarba A. 1997. Semisynthetic glycopeptides: chemistry, structure-activity relationships and prospects. Farmaco 52:313-321.
6. Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW. 2014. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med 370:2169-2179. http://dx.doi.org/10.1056/NEJMoa1310480.
7. th informational supplement. CLSI document M100-S24. Clinical and Laboratory Standards Institute, Wayne, PA. http://www.ncipd.org/UserFiles/CLSI-M100-S24.pdf.
8. Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard: ninth edition. LSI document M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA. http://antimicrobianos.com.ar/ATB/wp-content/uploads/2012/11/03-CLSI-M07-A9-2012.pdf.
9. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. 2012. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18: 268-281. http://dx.doi.org/10.1111/j.1469-0691.2011.03570.x.
10. Wyeth Pharmaceuticals. 2013. Tygacil (tigecycline) for injection for intravenous use. Wyeth Pharmaceuticals, Philadelphia, PA. http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/021821s021lbl.pdf.